These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28549516)

  • 1. Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6.
    Kong X; Strauss RW; Cideciyan AV; Michaelides M; Sahel JA; Munoz B; Ahmed M; Ervin AM; West SK; Cheetham JK; Scholl HPN;
    Ophthalmology; 2017 Nov; 124(11):1640-1651. PubMed ID: 28549516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.
    Kong X; Fujinami K; Strauss RW; Munoz B; West SK; Cideciyan AV; Michaelides M; Ahmed M; Ervin AM; Schönbach E; Cheetham JK; Scholl HPN;
    JAMA Ophthalmol; 2018 Aug; 136(8):920-928. PubMed ID: 29902293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2).
    Kong X; Strauss RW; Michaelides M; Cideciyan AV; Sahel JA; Muñoz B; West S; Scholl HP;
    Ophthalmology; 2016 Sep; 123(9):1887-97. PubMed ID: 27378015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
    Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
    Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
    Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric Inter-Eye Progression in Stargardt Disease.
    Lambertus S; Bax NM; Groenewoud JM; Cremers FP; van der Wilt GJ; Klevering BJ; Theelen T; Hoyng CB
    Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6824-6830. PubMed ID: 28002570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Progression of Stargardt Disease as Determined by Spectral-Domain Optical Coherence Tomography over a 24-Month Period (ProgStar Report No. 18).
    Strauss RW; Lang L; Ho A; Jha A; Ip M; Bernstein PS; Birch DG; Cideciyan AV; Michaelides M; Audo I; Sunness JS; Traboulsi EI; Zrenner E; Sadda SR; Janeschitz-Kriegl L; West S; Kong X; Scholl HPN;
    Ophthalmic Res; 2024; 67(1):435-447. PubMed ID: 39004077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeatability and Agreement of Visual Acuity Using the ETDRS Number Chart, Landolt C Chart, or ETDRS Alphabet Chart in Eyes With or Without Sight-Threatening Diseases.
    Chaikitmongkol V; Nanegrungsunk O; Patikulsila D; Ruamviboonsuk P; Bressler NM
    JAMA Ophthalmol; 2018 Mar; 136(3):286-290. PubMed ID: 29346499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
    Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
    Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixation Location and Stability Using the MP-1 Microperimeter in Stargardt Disease: ProgStar Report No. 3.
    Schönbach EM; Ibrahim MA; Strauss RW; Birch DG; Cideciyan AV; Hahn GA; Ho A; Kong X; Nasser F; Sunness JS; Zrenner E; Sadda SR; West SK; Scholl HPN;
    Ophthalmol Retina; 2017; 1(1):68-76. PubMed ID: 31047397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of estimated retinal atrophy progression in Stargardt macular dystrophy using spectral-domain optical coherence tomography.
    Strauss RW; Muñoz B; Wolfson Y; Sophie R; Fletcher E; Bittencourt MG; Scholl HP
    Br J Ophthalmol; 2016 Jul; 100(7):956-962. PubMed ID: 26568636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
    Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN; Chang L; Day BM; Ghanekar A; Stoilov I
    Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
    Schönbach EM; Strauss RW; Muñoz B; Wolfson Y; Ibrahim MA; Birch DG; Zrenner E; Sunness JS; Ip MS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2020 Jul; 138(7):772-779. PubMed ID: 32463436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Changes of Fixation Location and Stability Within 12 Months in Stargardt Disease: ProgStar Report No. 12.
    Schönbach EM; Strauss RW; Kong X; Muñoz B; Ibrahim MA; Sunness JS; Birch DG; Hahn GA; Nasser F; Zrenner E; Sadda SR; West SK; Scholl HPN;
    Am J Ophthalmol; 2018 Sep; 193():54-61. PubMed ID: 29890160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Progression of Stargardt Disease Using Volumetric Hill of Vision Analyses Over 24 Months: ProgStar Report No.15.
    Schönbach EM; Janeschitz-Kriegl L; Strauss RW; Cattaneo MEGV; Fujinami K; Birch DG; Cideciyan AV; Sunness JS; Weleber RG; Ip MS; Sadda SR; Scholl HPN;
    Am J Ophthalmol; 2021 Oct; 230():123-133. PubMed ID: 33951446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1).
    Strauss RW; Muñoz B; Ahmed MI; Bittencourt M; Schönbach EM; Michaelides M; Birch D; Zrenner E; Ervin AM; Charbel Issa P; Kong J; Wolfson Y; Shah M; Bagheri S; West S; Scholl HPN;
    Ophthalmic Res; 2018; 60(3):185-194. PubMed ID: 30110705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
    JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
    Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.